Evaxion expands AI-Immunology™ platform into autoimmune diseases

Rhea-AI Summary

Evaxion (NASDAQ: EVAX) is expanding its proprietary AI-Immunology™ platform to include autoimmune diseases, adding a third core disease area alongside cancer and infectious disease.

The company plans to expand and train the platform for autoimmune applications in the second half of 2026. Evaxion says this work is included in its cashflow outlook and does not change cash runway, which extends into the second half of 2027. The move aims to increase program quantity and partnership potential.

Key 2026 milestones target H1 and H2 events, including additional EVX-01 biomarker data, EVX-01 three-year phase 2 efficacy data (H2), a regulatory filing for EVX-04 phase 1 (H2), and EVX-B4 antigen design and preclinical validation (H2).

Positive

• Platform expansion to autoimmune diseases planned for H2 2026
• Cash runway confirmed into the second half of 2027
• Multiple 2026 milestones scheduled, including EVX-01 biomarker and phase 2 data

Negative

• Multiple key milestones concentrated in H2 2026, increasing near-term execution risk
• No new financing announced; runway only extends to the second half of 2027

News Market Reaction

-1.54%

1 alert

-1.54% News Effect

On the day this news was published, EVAX declined 1.54%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Cash runway: second half of 2027 EVX-01 efficacy horizon: three-year Autoimmune AI expansion timing: H2 2026 +1 more

4 metrics

Cash runway second half of 2027 Management states runway extends into H2 2027

EVX-01 efficacy horizon three-year Phase 2 clinical efficacy data planned in 2026

Autoimmune AI expansion timing H2 2026 Plan to expand and train AI-Immunology™ for autoimmune diseases

2026 milestones 5 program milestones EVX-01, AI-Immunology™, EVX-04, EVX-B4 targets outlined for 2026

Market Reality Check

Price: $4.68 Vol: Volume 49,326 is below th...

low vol

$4.68 Last Close

Volume Volume 49,326 is below the 20-day average of 85,178, suggesting only moderate pre-news interest. low

Technical At $5.18, EVAX trades above its $3.61 200-day MA but remains 57.37% below its 52-week high.

Peers on Argus

EVAX is up 1.97% while key peers show mixed moves: GOVX +5.62%, IBIO +2.27%, LST...

EVAX is up 1.97% while key peers show mixed moves: GOVX +5.62%, IBIO +2.27%, LSTA +4%, but PULM -1.26% and SYBX -2.59%, pointing to stock-specific drivers.

Historical Context

5 past events · Latest: Jan 07 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 07	Milestones presentation	Neutral	+6.7%	Outlined 2026 milestones and investor engagement at Biotech Showcase.
Dec 19	Collaboration update	Negative	-18.3%	MSD declined EVX-B2 option; Evaxion retained rights and seeks partner.
Nov 20	Preclinical data	Positive	+9.4%	Reported positive CMV vaccine EVX-V1 antigen data from AI-Immunology™.
Nov 12	Financial calendar	Neutral	+0.7%	Published 2026 financial calendar and key reporting dates.
Nov 07	Clinical data update	Positive	+1.9%	Presented new EVX-01 phase 2 biomarker and immune response data.

Pattern Detected

Recent Evaxion news—particularly AI and pipeline updates—has generally seen price moves that align with the news tone, with notable upside on positive R&D disclosures.

Recent Company History

Over the last few months, Evaxion has highlighted multiple milestones tied to its AI-Immunology™ platform. On Nov 7, 2025, positive immune data from the phase 2 EVX-01 trial aligned with a 1.92% gain. New CMV vaccine data on Nov 20, 2025 coincided with a 9.43% rise. An MSD collaboration update on Dec 19, 2025 brought a more negative -18.26% move. A milestones-focused conference update on Jan 7, 2026 preceded a 6.73% increase. Today’s platform expansion into autoimmune diseases fits this sequence of strategy- and AI-driven developments.

Market Pulse Summary

This announcement expands Evaxion’s AI-Immunology™ platform into autoimmune diseases, adding a third...

Analysis

This announcement expands Evaxion’s AI-Immunology™ platform into autoimmune diseases, adding a third core area alongside cancer and infectious disease. Management highlights a cash runway into the second half of 2027 and lays out 2026 milestones, including new EVX-01 data and an EVX-04 regulatory filing. In context of prior AI-driven pipeline updates, investors may watch how effectively the company trains its platform for autoimmune indications and delivers on the outlined H1 and H2 2026 objectives.

Key Terms

ai-immunology™, autoimmune diseases, biomarker, immunogenicity, +4 more

8 terms

ai-immunology™ technical

"Evaxion’s proprietary AI-Immunology™ platform will enable the discovery and development"

ai-immunology™ is the use of artificial intelligence techniques to analyze immune system data and guide the discovery, design and testing of immune-based diagnostics, vaccines and therapies. It matters to investors because it can speed up research, reduce costs and reveal promising drug targets that traditional methods might miss—like using a powerful search engine to find a few needles in a vast haystack of biological signals—potentially increasing the chance and pace of commercial returns.

autoimmune diseases medical

"Evaxion will expand the use of its proprietary AI-Immunology™ platform to also discover and develop new treatments for autoimmune diseases."

Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own cells, tissues or organs, causing chronic inflammation and damage—think of the immune system as a home security system that wrongly targets the house instead of intruders. Investors care because these illnesses create sustained demand for diagnostics, long-term treatments and specialty drugs, influence regulatory scrutiny and healthcare costs, and can shape the commercial outlook for biotech and pharmaceutical investments.

biomarker medical

"EVX-01 | Additional biomarker and immunogenicity data | H1"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

immunogenicity medical

"EVX-01 | Additional biomarker and immunogenicity data | H1"

Immunogenicity is the ability of a substance, such as a vaccine or medication, to provoke an immune response in the body. It matters to investors because high immunogenicity can affect the effectiveness and safety of a product, potentially leading to increased costs or regulatory challenges. Understanding immunogenicity helps assess the long-term viability and market potential of pharmaceutical and biotech investments.

phase 2 clinical efficacy medical

"EVX-01 | Three-year phase 2 clinical efficacy data | H2"

Phase 2 clinical efficacy measures whether a new drug or medical treatment produces the intended benefit in patients, typically tested in a modest-sized group to see if the therapy actually works and at what dose. Investors care because positive phase 2 efficacy is like a prototype passing functional tests — it materially raises the chance a product can advance toward approval and future sales, while failures often reduce a program’s value.

regulatory filing regulatory

"EVX-04 | Regulatory filing for phase 1 trial | H2"

A regulatory filing is an official document a company submits to government regulators that discloses material information about its finances, business activities, leadership, legal matters, or major transactions. Think of it as a public report card and notice to the referee — it lets investors see verified facts and changes that could affect a company’s value, helping them judge risk, spot opportunities, and make informed trading or investment decisions.

preclinical validation medical

"EVX-B4 | Design and preclinical validation of antigens | H2"

Preclinical validation is the set of laboratory and animal tests that show a drug, medical device, or therapy works and appears safe enough to try in humans. It matters to investors because positive preclinical results reduce technical and regulatory risk—like proving a prototype works in controlled tests before mass production—and help determine whether a development program is likely to advance to costly human trials and attract funding.

antigens medical

"EVX-B4 | Design and preclinical validation of antigens | H2"

Antigens are molecules—often proteins—on the surface of viruses, bacteria, or abnormal cells that the immune system recognizes as foreign, like a mugshot or ID badge that flags an intruder. For investors, antigens matter because they are the targets for vaccines, diagnostic tests and many biologic drugs; which antigen is involved affects how well a product works, how regulators evaluate it and how large the market opportunity may be.

AI-generated analysis. Not financial advice.

• Evaxion adds autoimmune disease as a third disease area as it expands its therapeutic focus
• In future, Evaxion’s proprietary AI-Immunology™ platform will enable the discovery and development of drug candidates targeting cancer, infectious and autoimmune diseases, leveraging its unique scalability
• Autoimmune diseases represent a high unmet medical need and offer significant partnership potential across all stages of drug development
• Evaxion also announces additional 2026 company milestones and maintains cash runway into second half of 2027

COPENHAGEN, Denmark, January 13, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will expand the use of its proprietary AI-Immunology™ platform to also discover and develop new treatments for autoimmune diseases. Thus, Evaxion will in the future work within cancers, infectious and autoimmune diseases as its core disease areas.

The expansion leverages the unique scalability of AI-Immunology™ and will increase the pool of diseases for which we can decode the immune system and potentially discover and develop new treatments. In turn, this will improve the quantity and quality of new programs within our pipeline, potentially available for partnership. Autoimmune diseases are characterized by high unmet medical need and offer significant partnership potential across all stages of drug development.

“Autoimmune diseases can be severely debilitating and even lethal, placing a substantial burden on patients, their families and on society across all stages of life. With AI-Immunology™ we have a unique technology and a platform that we know can deliver new treatment opportunities. By expanding the platform into autoimmune diseases, we have the potential to meaningfully improve the outcome for patients and unlock significant partnership value from the platform,” says Helen Tayton-Martin, CEO at Evaxion.

We plan to expand and train AI-Immunology™ to be applicable to autoimmune diseases during the second half of 2026. Specifically, the AI-Immunology™ platform potentially allows for development of precision treatments targeting underlying disease mechanisms, in contrast to current treatment approaches that primarily address symptoms. The related work on the autoimmune disease application development is already included in Evaxion’s cashflow outlook and does not impact our cash runway, which still extends to the second half of 2027.

2026 company milestones
The expansion to autoimmune diseases represents a new strategic milestone for Evaxion in addition to other milestones for 2026 as outlined below. These reflect continued execution of our strategy of creating value from both our platform and pipeline assets through partnerships.

	Milestone	Target
EVX-01	Additional biomarker and immunogenicity data	H1
AI-Immunology™	New application for autoimmune diseases	H2
EVX-01	Three-year phase 2 clinical efficacy data	H2
EVX-04	Regulatory filing for phase 1 trial	H2
EVX-B4	Design and preclinical validation of antigens	H2

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

FAQ

What did Evaxion (EVAX) announce on January 13, 2026 about its AI-Immunology™ platform?

Evaxion announced expansion of AI-Immunology™ to include autoimmune diseases, adding a third core disease area alongside cancer and infectious disease.

When will Evaxion train AI-Immunology™ for autoimmune diseases (EVAX)?

Evaxion plans to expand and train the platform for autoimmune disease applications in the second half of 2026.

How long is Evaxion's (EVAX) cash runway after the January 13, 2026 update?

Evaxion says its cash runway extends into the second half of 2027 and the autoimmune work is included in that outlook.

Which 2026 milestones did Evaxion (EVAX) list that may affect investors?

Milestones include EVX-01 biomarker and immunogenicity data (H1), EVX-01 three-year phase 2 efficacy data (H2), EVX-04 phase 1 regulatory filing (H2), and EVX-B4 antigen design/preclinical validation (H2).

Does Evaxion (EVAX) expect the autoimmune expansion to change its cash runway?

No; Evaxion states the autoimmune application development is included in its cashflow outlook and does not impact the cash runway into H2 2027.